Allogene Therapeutics' GAAP loss for 6 months of 2022 was $154.64 million, up 48.8% from $103.95 million in the previous year. Revenues declined multiple times, totaling $0.147 million versus $38.389 million a year earlier.
Allogene Therapeutics' GAAP loss for 6 months of 2022 was $154.64 million, up 48.8% from $103.95 million in the previous year. Revenues declined multiple times, totaling $0.147 million versus $38.389 million a year earlier. 
ir.allogene.com
English (US) 